Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
for Chronic Obstructive Pulmonary Disease
52 locations incl. Birmingham
Sponsor: Sanofi
Sex: All·Age: 40 - 80
Code: NCT07190222·Phase 3·Recruiting·Listed Sep 2025